Insulet Corporation — FY2015 Form 10-K
Business and reporting period: Fiscal year ended December 31, 2015; the filing also reports unaudited fourth-quarter results. Insulet develops, manufactures and sells the tubeless OmniPod insulin delivery system, alongside drug-delivery products and diabetes supplies. In July 2015, it took over Canadian distribution. In February 2016, after year-end, it sold Neighborhood Diabetes to Liberty Medical for approximately $5 million; that business was to be reported as discontinued operations beginning in Q1 2016.
Financial performance
Amounts are in U.S. dollars. FY2015 revenue rose 12% to $324.2 million, while the company remained loss-making and cash from operations turned negative.
| Metric | FY2015 | FY2014 |
|---|---|---|
| Revenue | $324.2 million | $288.7 million |
| Gross profit / gross margin | $148.2 million / 45.7% | $143.3 million / 49.6% |
| Operating loss | $60.8 million | $12.3 million |
| Net loss | $73.5 million | $51.5 million |
| Cash from (used in) operating activities | $(12.6) million | $8.9 million |
| Cash and cash equivalents at year-end | $122.7 million | $151.2 million |
| Working capital at year-end | $125.6 million | $163.9 million |
Q4 2015 revenue was $100.1 million, gross profit $45.3 million and net loss $27.3 million, compared with Q4 2014 revenue of $72.6 million, gross profit of $36.7 million and net loss of $5.4 million. The Q4 2015 net loss included a $9.1 million Neighborhood Diabetes impairment.
FY2015 revenue mix: U.S. OmniPod $186.8 million; international OmniPod $40.3 million; drug delivery $34.0 million; and Neighborhood Diabetes $63.1 million. The company reported total liabilities of $241.1 million and stockholders’ equity of $34.1 million at year-end. Convertible notes had $201.3 million principal, carried at $171.7 million net of discount and financing costs; capital lease obligations totaled approximately $5.8 million.
Changes versus prior year
- Revenue increased $35.5 million, led by U.S. OmniPod growth and drug-delivery sales. U.S. OmniPod revenue grew 8%; international OmniPod revenue fell 19%, mainly due to distributor ordering patterns.
- Drug-delivery revenue increased $28.6 million to $34.0 million after regulatory approval of a partner product in December 2014.
- Gross margin declined 3.9 percentage points. The company attributed this chiefly to approximately $11.5 million of costs associated with product quality actions, and higher warranty expense.
- Operating expenses increased 34% to $208.9 million, including higher R&D and sales and marketing spending. Operating loss widened substantially.
- Operating cash flow deteriorated from $8.9 million provided in 2014 to $12.6 million used in 2015; cash declined by $28.5 million during 2015.
Outlook, risks and unusual items
- Management expected strong 2016 revenue growth in continuing operations across product lines, citing U.S. and international expansion and increasing drug-delivery sales. It expected gross margin to improve, while R&D, sales and marketing, and G&A expenses were also expected to increase. The company expected near-term net losses to continue.
- Management stated that cash, cash equivalents and expected sales would cover projected operating and debt-service requirements for at least the next 12 months; elsewhere it described cash sufficiency through at least the end of 2016.
- Development priorities included a new PDM and mobile applications, continuous glucose monitoring integration, an artificial-pancreas program, and concentrated-insulin delivery with Eli Lilly. These programs remained subject to development and regulatory uncertainty.
- Product-quality actions included a July field removal and an October 2015 field correction after reports of cannula/needle deployment failures. In November, the company identified 18 distributed lots and 41 additional lots held before distribution; the latter were to be scrapped. Related costs included approximately $11.5 million charged to cost of revenue.
- The FDA issued a June 2015 Warning Letter following an inspection; Insulet said it had completed its response commitments but had not received notice that the letter was closed. A November–December 2015 inspection resulted in four additional Form 483 observations, to which the company responded in December.
- Other exposures include dependence on a single complete-Pod manufacturer in China and certain sole-source suppliers, third-party reimbursement and distributor relationships, and competition. Two customers represented 11% and 10% of FY2015 revenue.
- The company accrued $1.7 million for four Medicaid and sales-tax audits. One shareholder class-action lawsuit remained pending, and the company said it could not reasonably estimate a possible loss. The filing also describes ongoing reimbursement, regulatory, product-liability and intellectual-property risks.
Important facts for investors to verify
- Whether 2016 growth and gross-margin improvement materialized after Neighborhood Diabetes was sold and excluded from continuing operations.
- Resolution and financial impact of the FDA Warning Letter, subsequent inspection observations, and OmniPod field actions.
- Cash burn, liquidity and ability to service or refinance the $201.3 million convertible-note principal due in 2019, including capital-lease obligations.
- Drivers of customer starts, retention and recurring revenue, and the effect of international distributor ordering and reimbursement coverage.
- Outcome and potential cost of the pending shareholder lawsuit and the Medicaid and tax audits.